AustralieFrV1, Main, Exploration, bibRecord, 005E15

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial

Identifieur interne : 005E15 ( Main/Exploration ); précédent : 005E14; suivant : 005E16

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial

Auteurs : L. Gladieff [France] ; A. Ferrero [Italie] ; G. De Rauglaudre [France] ; C. Brown [Australie] ; P. Vasey [Australie] ; A. Reinthaller [Autriche] ; E. Pujade-Lauraine [France] ; N. Reed [Royaume-Uni] ; D. Lorusso [Italie] ; S. Siena [Italie] ; H. Helland [Norvège] ; L. Elit [Canada] ; S. Mahner [Allemagne]

Source :

Annals of oncology [ 0923-7534 ] ; 2012.

RBID : Pascal:12-0212499

Descripteurs français

Pascal (Inist)
- Carboplatine, Forme pégylée, Liposome, Doxorubicine, Etude comparative, Paclitaxel, Cancer de l'ovaire, Homme, Malade, Analyse, Essai clinique phase III, Chimiothérapie, Anticancéreux.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Analysis, Antineoplastic agent, Carboplatin, Chemotherapy, Comparative study, Doxorubicin, Human, Liposome, Ovary cancer, Paclitaxel, Patient, Pegylated form, Phase III trial.

Abstract

Background: To perform a subset analysis of patients with partially platinum-sensitive recurrent ovarian cancer (ROC) who received either CD [carboplatin-pegylated liposomal doxorubicin (PLD)] or CP (carboplatin-paclitaxel) in the CALYPSO trial. Patients and methods: CALYPSO, an international phase III, non-inferiority trial, enrolled women with ROC that relapsed >6 months following first- or second-line therapy. Patients were randomized to CD or CP. Patients with a treatment-free interval of >6 and ≤12 months were evaluated for progression-free survival (PFS), the primary end point of CALYPSO trial, and safety. Results: A total of 344 partially platinum-sensitive patients were included (N = 161, CD and N = ₁₈₃, CP). The hazard ratio for PFS was 0.73 (95% confidence interval: 0.58-0.90; P = 0.004 for superiority) in favor of CD. Median PFS times were 9.4 months (CD) and 8.8 months (CP). Toxicities more common with CP versus CD included grade 3/4 neutropenia (50% versus 39%; P = 0.015), grade 2 alopecia (86% versus 9%; P < 0.001), neuropathy and hypersensitivity reactions. Hand-foot syndrome was more common with CD; however, grade 3/4 reactions were low (one patient in each arm). Conclusion: Carboplatin-PLD has a more favorable risk-benefit profile than CP in patients with partially platinum-sensitive ROC and should be considered an effective treatment option for these patients.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001389
to stream PascalFrancis, to step Curation: 004B24
to stream PascalFrancis, to step Checkpoint: 001301
to stream Main, to step Merge: 006136
to stream Main, to step Curation: 005E15

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial</title>
<author><name sortKey="Gladieff, L" sort="Gladieff, L" uniqKey="Gladieff L" first="L." last="Gladieff">L. Gladieff</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Medical Oncology, Institut Claudius Regaud</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferrero, A" sort="Ferrero, A" uniqKey="Ferrero A" first="A." last="Ferrero">A. Ferrero</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Academic Division of Gynecologic Oncology, Mauriziano Hospital</s1>
<s2>Torino</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Turin</settlement>
<region type="région" nuts="2">Piémont</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Rauglaudre, G" sort="De Rauglaudre, G" uniqKey="De Rauglaudre G" first="G." last="De Rauglaudre">G. De Rauglaudre</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of clinical Oncology, Institut Sainte-Catherine</s1>
<s2>Avignon</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Avignon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brown, C" sort="Brown, C" uniqKey="Brown C" first="C." last="Brown">C. Brown</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>NHMRC Clinical Trials Centre</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vasey, P" sort="Vasey, P" uniqKey="Vasey P" first="P." last="Vasey">P. Vasey</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>University of Queensland</s1>
<s2>Brisbane</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>University of Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Reinthaller, A" sort="Reinthaller, A" uniqKey="Reinthaller A" first="A." last="Reinthaller">A. Reinthaller</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Gynecology and Gynecologic Oncology, Medical University of Vienna - General Hospital of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E." last="Pujade-Lauraine">E. Pujade-Lauraine</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Medical Oncology, Medicale Hopital Hotel-Dieu and Universite Paris Descartes</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Reed, N" sort="Reed, N" uniqKey="Reed N" first="N." last="Reed">N. Reed</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Gartnavel General Hospital, Beatson Oncology Centre</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lorusso, D" sort="Lorusso, D" uniqKey="Lorusso D" first="D." last="Lorusso">D. Lorusso</name>
<affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Department of Obstetrics and Gynecology, University of Sacred Heart</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Siena, S" sort="Siena, S" uniqKey="Siena S" first="S." last="Siena">S. Siena</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Oncology, Ospedale Niguarda Ca' Granda</s1>
<s2>Milano</s2>
<s3>ITA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Milano</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Helland, H" sort="Helland, H" uniqKey="Helland H" first="H." last="Helland">H. Helland</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Obstetrics and Gynecology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Bergen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Elit, L" sort="Elit, L" uniqKey="Elit L" first="L." last="Elit">L. Elit</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Gynecologic Oncology, Juravinski Cancer Centre</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Hamilton</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mahner, S" sort="Mahner, S" uniqKey="Mahner S" first="S." last="Mahner">S. Mahner</name>
<affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><settlement type="city">Hambourg</settlement>
<region type="land" nuts="2">Hambourg</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0212499</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0212499 INIST</idno>
<idno type="RBID">Pascal:12-0212499</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001389</idno>
<idno type="wicri:Area/PascalFrancis/Curation">004B24</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001301</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001301</idno>
<idno type="wicri:doubleKey">0923-7534:2012:Gladieff L:carboplatin:and:pegylated</idno>
<idno type="wicri:Area/Main/Merge">006136</idno>
<idno type="wicri:Area/Main/Curation">005E15</idno>
<idno type="wicri:Area/Main/Exploration">005E15</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial</title>
<author><name sortKey="Gladieff, L" sort="Gladieff, L" uniqKey="Gladieff L" first="L." last="Gladieff">L. Gladieff</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Medical Oncology, Institut Claudius Regaud</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferrero, A" sort="Ferrero, A" uniqKey="Ferrero A" first="A." last="Ferrero">A. Ferrero</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Academic Division of Gynecologic Oncology, Mauriziano Hospital</s1>
<s2>Torino</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Turin</settlement>
<region type="région" nuts="2">Piémont</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Rauglaudre, G" sort="De Rauglaudre, G" uniqKey="De Rauglaudre G" first="G." last="De Rauglaudre">G. De Rauglaudre</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of clinical Oncology, Institut Sainte-Catherine</s1>
<s2>Avignon</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Avignon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brown, C" sort="Brown, C" uniqKey="Brown C" first="C." last="Brown">C. Brown</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>NHMRC Clinical Trials Centre</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vasey, P" sort="Vasey, P" uniqKey="Vasey P" first="P." last="Vasey">P. Vasey</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>University of Queensland</s1>
<s2>Brisbane</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>University of Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Reinthaller, A" sort="Reinthaller, A" uniqKey="Reinthaller A" first="A." last="Reinthaller">A. Reinthaller</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Gynecology and Gynecologic Oncology, Medical University of Vienna - General Hospital of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E." last="Pujade-Lauraine">E. Pujade-Lauraine</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Medical Oncology, Medicale Hopital Hotel-Dieu and Universite Paris Descartes</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Reed, N" sort="Reed, N" uniqKey="Reed N" first="N." last="Reed">N. Reed</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Gartnavel General Hospital, Beatson Oncology Centre</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lorusso, D" sort="Lorusso, D" uniqKey="Lorusso D" first="D." last="Lorusso">D. Lorusso</name>
<affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Department of Obstetrics and Gynecology, University of Sacred Heart</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Siena, S" sort="Siena, S" uniqKey="Siena S" first="S." last="Siena">S. Siena</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Oncology, Ospedale Niguarda Ca' Granda</s1>
<s2>Milano</s2>
<s3>ITA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Milano</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Helland, H" sort="Helland, H" uniqKey="Helland H" first="H." last="Helland">H. Helland</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Obstetrics and Gynecology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Bergen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Elit, L" sort="Elit, L" uniqKey="Elit L" first="L." last="Elit">L. Elit</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Gynecologic Oncology, Juravinski Cancer Centre</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Hamilton</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mahner, S" sort="Mahner, S" uniqKey="Mahner S" first="S." last="Mahner">S. Mahner</name>
<affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><settlement type="city">Hambourg</settlement>
<region type="land" nuts="2">Hambourg</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis</term>
<term>Antineoplastic agent</term>
<term>Carboplatin</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>Doxorubicin</term>
<term>Human</term>
<term>Liposome</term>
<term>Ovary cancer</term>
<term>Paclitaxel</term>
<term>Patient</term>
<term>Pegylated form</term>
<term>Phase III trial</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Carboplatine</term>
<term>Forme pégylée</term>
<term>Liposome</term>
<term>Doxorubicine</term>
<term>Etude comparative</term>
<term>Paclitaxel</term>
<term>Cancer de l'ovaire</term>
<term>Homme</term>
<term>Malade</term>
<term>Analyse</term>
<term>Essai clinique phase III</term>
<term>Chimiothérapie</term>
<term>Anticancéreux</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: To perform a subset analysis of patients with partially platinum-sensitive recurrent ovarian cancer (ROC) who received either CD [carboplatin-pegylated liposomal doxorubicin (PLD)] or CP (carboplatin-paclitaxel) in the CALYPSO trial. Patients and methods: CALYPSO, an international phase III, non-inferiority trial, enrolled women with ROC that relapsed >6 months following first- or second-line therapy. Patients were randomized to CD or CP. Patients with a treatment-free interval of >6 and ≤12 months were evaluated for progression-free survival (PFS), the primary end point of CALYPSO trial, and safety. Results: A total of 344 partially platinum-sensitive patients were included (N = 161, CD and N = <sub>183</sub>
, CP). The hazard ratio for PFS was 0.73 (95% confidence interval: 0.58-0.90; P = 0.004 for superiority) in favor of CD. Median PFS times were 9.4 months (CD) and 8.8 months (CP). Toxicities more common with CP versus CD included grade 3/4 neutropenia (50% versus 39%; P = 0.015), grade 2 alopecia (86% versus 9%; P < 0.001), neuropathy and hypersensitivity reactions. Hand-foot syndrome was more common with CD; however, grade 3/4 reactions were low (one patient in each arm). Conclusion: Carboplatin-PLD has a more favorable risk-benefit profile than CP in patients with partially platinum-sensitive ROC and should be considered an effective treatment option for these patients.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Autriche</li>
<li>Canada</li>
<li>France</li>
<li>Italie</li>
<li>Norvège</li>
<li>Royaume-Uni</li>
</country>
<region><li>Hambourg</li>
<li>Latium</li>
<li>Midi-Pyrénées</li>
<li>Nouvelle-Galles du Sud</li>
<li>Occitanie (région administrative)</li>
<li>Piémont</li>
<li>Provence-Alpes-Côte d'Azur</li>
<li>Vienne (Autriche)</li>
<li>Île-de-France</li>
</region>
<settlement><li>Avignon</li>
<li>Hambourg</li>
<li>Paris</li>
<li>Rome</li>
<li>Sydney</li>
<li>Toulouse</li>
<li>Turin</li>
<li>Vienne (Autriche)</li>
</settlement>
</list>
<tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Gladieff, L" sort="Gladieff, L" uniqKey="Gladieff L" first="L." last="Gladieff">L. Gladieff</name>
</region>
<name sortKey="De Rauglaudre, G" sort="De Rauglaudre, G" uniqKey="De Rauglaudre G" first="G." last="De Rauglaudre">G. De Rauglaudre</name>
<name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E." last="Pujade-Lauraine">E. Pujade-Lauraine</name>
</country>
<country name="Italie"><region name="Piémont"><name sortKey="Ferrero, A" sort="Ferrero, A" uniqKey="Ferrero A" first="A." last="Ferrero">A. Ferrero</name>
</region>
<name sortKey="Lorusso, D" sort="Lorusso, D" uniqKey="Lorusso D" first="D." last="Lorusso">D. Lorusso</name>
<name sortKey="Siena, S" sort="Siena, S" uniqKey="Siena S" first="S." last="Siena">S. Siena</name>
</country>
<country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Brown, C" sort="Brown, C" uniqKey="Brown C" first="C." last="Brown">C. Brown</name>
</region>
<name sortKey="Vasey, P" sort="Vasey, P" uniqKey="Vasey P" first="P." last="Vasey">P. Vasey</name>
</country>
<country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Reinthaller, A" sort="Reinthaller, A" uniqKey="Reinthaller A" first="A." last="Reinthaller">A. Reinthaller</name>
</region>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Reed, N" sort="Reed, N" uniqKey="Reed N" first="N." last="Reed">N. Reed</name>
</noRegion>
</country>
<country name="Norvège"><noRegion><name sortKey="Helland, H" sort="Helland, H" uniqKey="Helland H" first="H." last="Helland">H. Helland</name>
</noRegion>
</country>
<country name="Canada"><noRegion><name sortKey="Elit, L" sort="Elit, L" uniqKey="Elit L" first="L." last="Elit">L. Elit</name>
</noRegion>
</country>
<country name="Allemagne"><region name="Hambourg"><name sortKey="Mahner, S" sort="Mahner, S" uniqKey="Mahner S" first="S." last="Mahner">S. Mahner</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005E15 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005E15 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:12-0212499
   |texte=   Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri